A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea (OSA)
Latest Information Update: 26 Aug 2024
At a glance
- Drugs HRS 9531 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Fujian Shengdi Pharmaceutical
Most Recent Events
- 26 Aug 2024 New trial record